Near Complete Response to 177Lu-PSMA-DKFZ-617 Therapy in a Patient with Metastatic Castration Resistant Prostate Cancer
Open Access
- 1 January 2017
- journal article
- Published by Heighten Science Publications Corporation in Journal of Radiology and Oncology
- Vol. 1 (3), 083-086
- https://doi.org/10.29328/journal.jro.1001012
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617Journal of Nuclear Medicine, 2016
- 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and EfficacyJournal of Nuclear Medicine, 2016
- Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2015
- The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor LesionsJournal of Nuclear Medicine, 2015
- PSMA, EpCAM, VEGF and GRPR as Imaging Targets in Locally Recurrent Prostate Cancer after RadiotherapyInternational Journal of Molecular Sciences, 2014
- PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesionsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- Characterising the castration-resistant prostate cancer population: a systematic reviewInternational Journal of Clinical Practice, 2011
- Current Management of Castrate-Resistant Prostate CancerCurrent Oncology, 2010
- High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancerThe Prostate, 2010
- Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteriaInvestigational New Drugs, 1992